Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
Pengyun Li, Changkai Jia, Zhiya Fan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2715-2735
Open Access | Times Cited: 18

Showing 18 citing articles:

Rational Design, Synthesis, and Biological Evaluation of Novel c-Met Degraders for Lung Cancer Therapy
Xingyang Qiu, Qingquan Zheng, Dongdong Luo, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Application and challenges of nitrogen heterocycles in PROTAC linker
Yang Li, Junfeng Qu, Lizhi Jiang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116520-116520
Closed Access | Times Cited: 13
Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions
Abdulhameed Al‐Ghabkari, Bruce Huang, Morag Park
Cells (2024) Vol. 13, Iss. 3, pp. 218-218
Open Access | Times Cited: 10
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 9
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity
Jiankang Hu, Hongrui Xu, Tianbang Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 6952-6986
Closed Access | Times Cited: 8
Rational design of VHL-recruiting KRASG12C proteolysis-targeting chimeras based on molecular dynamics simulation
Shiyang Sun, Ning Yang, Yaqiu Mao, et al.
Chinese Chemical Letters (2025), pp. 110992-110992
Closed Access
Discovery of Novel Rigid STING PROTAC Degraders as Potential Therapeutics for Acute Kidney Injury
Rui Ma, Renquan Fu, Yifan Wang, et al.
European Journal of Medicinal Chemistry (2025), pp. 117539-117539
Closed Access
Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders
Jayapal Reddy Mallareddy, Lin Yang, Wan-Hsin Lin, et al.
RSC Advances (2025) Vol. 15, Iss. 13, pp. 10419-10425
Open Access
Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer
Lisha Ye, Wenjing Wang, Huihui Li, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 3
Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer
Yubo Wang, Mengmeng Wang, Ma Lan, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases
Lingfeng Chen, Ruixiang Luo, Lin Ma, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 8060-8076
Closed Access | Times Cited: 2
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
Pengyun Li, Bingkun Li, Ning Yang, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 7-8, pp. 477-492
Closed Access | Times Cited: 5
Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer
Zuoyang Wang, Zhichao Shi, Shiqi Yang, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 9, pp. 1516-1525
Closed Access | Times Cited: 1
Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma
Xuekun Fu, Jie Huang, Xinxin Chen, et al.
Theranostics (2024) Vol. 15, Iss. 1, pp. 103-121
Closed Access | Times Cited: 1
Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy
Linsheng Zhuo, Mengqin Guo, Siyi Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116090-116090
Closed Access | Times Cited: 2
Design and Synthesis of C-Mesenchymal Epithelial Transition Factor (C-Met) and Histone Deacetylase (Hdac) Dual Inhibitors for the Treatment of Breast Cancer
Zuoyang Wang, Zhichao Shi, Zizhou Niu, et al.
(2024)
Closed Access
Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer
Nicoletta Cordani, Daniele Nova, Luca Sala, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11214-11214
Open Access
Page 1

Scroll to top